Free Trial

Syndax Pharmaceuticals Q4 2024 Earnings Report

Syndax Pharmaceuticals logo
$12.95 -0.15 (-1.15%)
As of 03/14/2025 04:00 PM Eastern

Syndax Pharmaceuticals EPS Results

Actual EPS
-$1.10
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.79
One Year Ago EPS
N/A

Syndax Pharmaceuticals Revenue Results

Actual Revenue
$7.68 million
Expected Revenue
$86.32 million
Beat/Miss
Missed by -$78.64 million
YoY Revenue Growth
N/A

Syndax Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Syndax Pharmaceuticals Earnings Headlines

Research Analysts Issue Forecasts for SNDX FY2025 Earnings
Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
What is B. Riley's Forecast for SNDX Q3 Earnings?
Brokers Set Expectations for SNDX Q1 Earnings
Q1 Earnings Forecast for SNDX Issued By HC Wainwright
See More Syndax Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Syndax Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Syndax Pharmaceuticals and other key companies, straight to your email.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

View Syndax Pharmaceuticals Profile

More Earnings Resources from MarketBeat